NOVO NORDISK A/S
15.0 billion to be executed during a 12-month period beginning 30 January 2014.
Under the programme initiated 1 May 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 4.0 billion in the period from 1 May 2014 to 5 August 2014. The programme is now concluded.
Since the announcement as of 28 July 2014, the following transactions have been made under the programme:
28 July 2014 250,000 253.17 63,293,075
29 July 2014 250,000 256.55 64,137,550
30 July 2014 260,000 258.23 67,140,658
31 July 2014 260,000 257.92 67,059,252
1 August 2014 260,000 251.11 65,289,250
4 August 2014 260,000 251.90 65,495,274
5 August 2014 237,000 255.09 60,456,970
With the transactions stated above, Novo Nordisk owns a total of 34,741,014 B shares of DKK 0.20, corresponding to 1.3% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.
Novo Nordisk A/SInvestor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 47 / 2014
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 5 August 2014, Novo Nordisk has repurchased a total of 31,737,995 B shares equal to a transaction value of DKK
7,704,518,499.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately
40,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
Further informationMedia: | ||
Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
Investors: | ||
Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
Jannick Lindegaard Denholt | +45 3079 8519 | jlis@novonordisk.com |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com |
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 47 / 2014
|
distributed by
|
